What To Know
- Neuroglide’s patented system includes a Controller Unit, disruptive new valve module technology, and unique inflatable air channels which have been precisely engineered to deliver the proven benefits of MLD therapy in the comfort of one’s home, relieving pain without the need for pharmaceuticals or expensive in-person sessions while offering improved recovery and performance, relaxation, and stress relief.
- The Neuroglide Back/Neck Pad is the first of a system of automated therapy devices that provide effective, convenient, and sustainable pain management solutions for people living with chronic pain, who need to relax, relieve and recover.
Eva Medtec, Inc. is excited to announce that its flagship product, the Neuroglide Back/Neck Pad, is available for purchase by the general public.
Sporting an FDA clearance for pain relief, a limited, 250-unit release of this innovative neck and back pain therapy device can now be purchased here, with a $250.00 discount.
The Neuroglide Back/Neck Pad is the first of a system of automated therapy devices that provide effective, convenient, and sustainable pain management solutions for people living with chronic pain, who need to relax, relieve and recover.
The technology is designed to emulate a therapeutic modality called manual lymphatic drainage (MLD). MLD triggers the body’s parasympathetic nervous system, activating powerful natural relaxation and pain relief pathways.
Neuroglide’s patented system includes a Controller Unit, disruptive new valve module technology, and unique inflatable air channels which have been precisely engineered to deliver the proven benefits of MLD therapy in the comfort of one’s home, relieving pain without the need for pharmaceuticals or expensive in-person sessions while offering improved recovery and performance, relaxation, and stress relief.
Eva Medtec founder/CEO and Neuroglide inventor, Irene Waldridge, previously founded Tactile Medical, where she held four patents as the inventor of the Flexitouch® System for the treatment of lymphedema and venous insufficiency. Tactile Medical is currently valued at about $1B on revenues approximating $190M.
